MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
MK-1084 had an acceptable toxicity profile when administered as a monotherapy in patients with KRAS G12C–mutated previously treated solid malignancies.
MK-1084 had an acceptable toxicity profile when administered as a monotherapy in patients with KRAS G12C–mutated previously treated solid malignancies.
The 2024 ASTRO Annual Meeting will be held at the Walter E. Washington Convention Center, Washington, DC, and virtually September 29-October 2, 2024.
Foundation Blog Unbreakable Spirit: Samantha’s Triumph Over Cervical Cancer Samantha’s journey with cervical cancer began unexpectedly at the age of 27. “You have cervical cancer,”…
A list of current (APEx®) facilities.
PJ DiPentino made the seven-hour trek from his home in Montana to Huntsman Cancer Institute. After receiving a warm welcome, he underwent bladder surgery and…
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary…
PHILADELPHIA (May 10, 2024) — Kara Stromberg, MS, RD, LDN, CDCES, Director of Clinical Nutrition and Nutrition Research at Fox Chase Cancer Center and Temple…
Researchers explored the mediating role of health behaviors and depression, anxiety, and cancers.
Rosa Hwang, M.D., answers five questions about double mastectomy, including which patients may benefit from this breast cancer treatment option.
The Centers for Medicare & Medicaid Services recently issued a decision to expand Medicare coverage for allogeneic hematopoietic stem cell transplants for eligible Medicare patients…
Deric Park, MD, discusses what challenges remain in treating glioblastoma, as well as new avenues for research in this difficult disease.